This clinical trial focuses on studying the detection and classification of breast lesions using different imaging techniques. The study involves comparing Digital Mammography with Contrast Medium (CEDM), both alone and combined with Tomosynthesis, to Magnetic Resonance Imaging (MRI) that uses a substance called Gadolinium. The main goal is to evaluate how well these methods can identify and accurately diagnose breast conditions, including the presence of multiple tumors in one or both breasts.
The trial uses a special contrast agent called Visipaque, which contains the active substance iodixanol. This agent is injected into the body to help highlight areas of interest during imaging. The study aims to determine if CEDM, with or without tomosynthesis, is as effective as MRI in detecting and diagnosing breast lesions. Additionally, the study will assess the ability of these imaging techniques to classify breast lesions as benign or malignant and to identify specific tumor characteristics, such as luminal A, luminal B, HER2-positive, and triple-negative types.
Participants in the study will undergo imaging tests using the different methods mentioned. The study will compare the results to see which method provides the most accurate information about breast lesions. This research is important for improving the diagnosis and treatment planning for individuals with breast conditions, potentially leading to better outcomes and more personalized care.



Italy